Fusion Pharmaceuticals Enters Into Agreement To Build Radiopharmaceutical Manufacturing Facility

Ontario Industry Updates
Written By Doriane Rey
Fusion Pharma.png

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, recently announced it entered a 15-year lease agreement with Hamilton, Ontario-based McMaster University to build a 27,000 square foot current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility.

Doriane Rey
Previous

VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM
Next

Highmark Innovations Inc. Completes a Brokered Private Placement Financing, Closes Acquisition of BrainFx Inc. and Announces Future Acquisitions